Biomarkers in Kidney Cancer
A symposium presenting current state of the art and new directions for clinical and basic research
To be presented before KCRS in Boston, July 13, 2023
6:30–7:30am – Registration & Breakfast
7:30–10:30am – Symposium
BIOMARKER NEEDS AND OPPORTUNITIES IN KIDNEY CANCER RESEARCH
Kidney cancer remains one of the top 10 most common cancers in the U.S. Approximately $9.7 billion is spent annually on kidney cancer care. Although it is a relatively common malignancy, kidney cancer is a highly variable disease with unpredictable response to the available treatment regimes. There is a critical need for progress in biomarkers for kidney cancer treatment to enter into the era of personalized predictive tools. There are currently no biomarkers for guiding treatment selection in kidney cancer.
Identifying the most promising research to move emerging biomarker technologies into trials and clinical use is a driving force behind the decision to add a separate biomarker session to KCRS23. The location of this year’s KCRS23 meeting, near both the kidney cancer SPORE Dana-Farber Cancer Institute (DFCI) in Boston and the biotechnology industry hub in Cambridge, makes this the ideal time and place to devote a separate symposium to the vitally important topic. This session will attract industry partners and attendees from multiple disciplines focused on developing kidney cancer biomarkers.
Session 1
Biomarker Technologies in RCC
In this session, we explore projects at the preclinical stage of research with promise for future deployment in biomarkers for kidney cancer.
MODERATORS

TONI CHOUEIRI
Dana-Farber Cancer Institute

Mahrukh Huseni
Genentech
SPEAKERS

ARI HAKIMI
Memorial Sloan Kettering Cancer Center
Genomic DNA/RNA Biomarkers

Sabina Signoretti
Dana-Farber Cancer Institute
Spatial Biomarkers: Tissue-Based in situ Analyses including IF for Biomarker Development

David Braun
Yale Cancer Center
High-Dimensional/Spatial Tools for Biomarker Discovery in RCC

TIM SHOWALTER
Artera
How Can AI Guide Biomarker Development and Progress in RCC

HEATHER JACENE
Dana-Farber Cancer Institute
Developing Metabolic Imaging Agents in Kidney Cancer

HEDYEH EBRAHIMI
City of Hope Comprehensive Cancer Center
CT-Based Radiomics Model for the Prediction of Genomic Alterations in Renal Cell Carcinoma (RCC)

RENEE MARIA SALIBY
Dana-Farber Cancer Institute
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab Plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
discussion
Developing and Implementing New Technologies in Biomarker Research
Session 2
Clinical Biomarkers: Trial Data and Directions
In this session, we focus on biomarker data gleaned from recent clinical trials, describing both the methodology and results. The session closes with a discussion on integrating biomarker research into clinical trials, data sharing, specimen repositories, and other approaches to accelerate progress in this phase of biomarker development.
MODERATORS

TOM POWLES
Barts Cancer Centre

MEDHI MOLLAPOUR
State University of New York
SPEAKERS

TOM POWLES
Barts Cancer Centre
Emerging Biomarkers for the Ipi/Nivo: New Data from PRISM

DAVID McDERMOTT
Beth Israel Deaconess Medical Center
Learning from the Atezolizumab Biomarker Program in RCC: Lessons for Future Trial Designs

SAURABH GUPTA
Bristol Myers Squibb
Biomarkers for PD-1 Based Therapies in RCC

AXEL BEX
Royal Free Hospital, London
Designing Clinical Trials in the Perioperative Setting in RCC

SYLVAN BACA
Dana-Farber Cancer Institute
Development and Clinical Application of ctDNA in RCC

ALEXANDER GUSEV
Dana-Farber Cancer Institute
Biomarkers of Toxicity to Immune Checkpoint Blockers

VINCENT XU
Dana-Farber Cancer Institute
KIM 1 and Kidney Cancer: Multiple Setting or an Ideal Setting?

ADAM EINAGGER
Natera
Utilization of ctDNA for RCC Disease Monitoring and Treatment Response
discussion
Biomarker Research in Clinical Trials Planning